TGF-β/PI3K/AKT/mTOR/NF-kB pathway. Clinicopathological features in prostate cancer

References

• Molina-Garrido MJ, Guillén-Ponce C. Use of geriatric assessment and screening tools of frailty in elderly patients with prostate cancer. Review. Aging Male. 2017;20:102–109.
   PubMed Web of Science ®Google Scholar
• Nuñez C, Cansino JR, Bethencourt F, et al. TNF/IL-1/NIK/NF-kappa B transduction pathway: a comparative study in normal and pathological human prostate (benign hyperplasia and carcinoma). Histopathology. 2008;53:166–176.
   PubMed Web of Science ®Google Scholar
• Russo GI, Calogero AE, Condorelli RA, et al. Human papillomavirus and risk of prostate cancer: a systematic review and meta-analysis. Aging Male. 2018;23:1–7.
   Web of Science ®Google Scholar
• Pascual-Geler M, Urquiza-Salvat N, Cozar JM, et al. The influence of nutritional factors on prostate cancer incidence and aggressiveness. Aging Male. 2018;21:31–39.
   PubMed Web of Science ®Google Scholar
• Reis ST1, Pontes-Júnior J, Antunes AA, et al. TGF-β1 expression as a biomarker of poor prognosis in prostate cancer. Clinics (Sao Paulo). 2011;66:1143–1147.
   PubMed Web of Science ®Google Scholar
• Torrealba N, Rodríguez-Berriguete G, Fraile B, et al. Expression of several cytokines in prostate cancer: correlation with clinical variables of patients. Relationship with biochemical progression of the malignance. Cytokine. 2017;89:105–115.
   PubMed Web of Science ®Google Scholar
• Krstić J, Trivanović D, Mojsilović S, et al. Transforming growth factor-beta and oxidative stress interplay: implications in tumorigenesis and cancer progression. Oxid Med Cell Longev. 2015;2015:654594.
   PubMed Web of Science ®Google Scholar
• Li T, Wang G. Computer-aided targeting of the PI3K/AKT/mTOR pathway: toxicity reduction and therapeutic opportunities. Int J Mol Sci. 2014;15:18856–18891.
   PubMed Web of Science ®Google Scholar
• Torrealba N, Rodriguez-Berriguete G, Fraile B, et al. PI3K pathway and Bcl-2 family. Clinicopathological features in prostate cancer. Aging Male. 2018a;9:1–12.
   Web of Science ®Google Scholar
• Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer. 2015;15:7–24.
   PubMed Web of Science ®Google Scholar
• Mayer IA, Arteaga CL. The PI3K/AKT pathway as a target for cancer treatment. Annu Rev Med. 2016;67:11–28.
   PubMed Web of Science ®Google Scholar
• Cheaib B, Auguste A, Leary A. The PI3K/AKT/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges. Chin J Cancer. 2015;34:4–16.
   PubMed Web of Science ®Google Scholar
• Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012;13:283–296.
   PubMed Web of Science ®Google Scholar
• Okano J, Gaslightwala I, Birnbaum MJ, et al. AKT/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation. J Biol Chem. 2000;275:30934–30942.
   PubMed Web of Science ®Google Scholar
• Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007;129:1261–1274.
   PubMed Web of Science ®Google Scholar
• Tang JM, He QY, Guo RX, et al. Phosphorylated AKT overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer. 2006;51:181–191.
   PubMed Web of Science ®Google Scholar
• Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell. 2008;133:403–414.
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274–293.
   PubMed Web of Science ®Google Scholar
• Guo F. Mtor-Fanconi anemia DNA damage repair pathway in cancer. J Oncobiomarkers. 2014;2:5.
   PubMedGoogle Scholar
• Senegas A, Gautheron J, Maurin AG, et al. IKK-related genetic diseases: probing NF-κB functions in humans and other matters. Cell Mol Life Sci. 2015;72:1275–1287.
   PubMed Web of Science ®Google Scholar
• Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5:749–759.
   PubMed Web of Science ®Google Scholar
• Palkowitsch L, Leidner J, Ghosh S, et al. Phosphorylation of serine 68 in the IkappaB kinase (IKK)-binding domain of NEMO interferes with the structure of the IKK complex and tumor necrosis factor-alpha-induced NF-kappaB activity. J Biol Chem. 2008;283:76–86.
   PubMed Web of Science ®Google Scholar
• DiDonato JA, Mercurio F, Karin M. NF-κB and the link between inflammation and cancer. Immunol Rev. 2012;246:379–400.
   PubMed Web of Science ®Google Scholar
• Hoesel B, Schmid JA. The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer. 2013;12:86.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Berriguete G, Sánchez-Espiridión B, Cansino JR, et al. Clinical significance of both tumor and stromal expression of components of the IL-1 and TNF-α signaling pathways in prostate cancer. Cytokine. 2013;64:555–563.
   PubMed Web of Science ®Google Scholar
• Ricote M, García-Tuñón I, Bethencourt F, et al. The p38 transduction pathway in prostatic neoplasia. J Pathol. 2006;208:401–407.
   PubMed Web of Science ®Google Scholar
• Cheng L, Montironi R, Bostwick DG, et al. Staging of prostate cancer. Histopathology. 2012;60:87–117.
   PubMed Web of Science ®Google Scholar
• Epstein JI, Egevad L, Amin MB, et al. Grading Committee. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2014;40:244–252.
   Web of Science ®Google Scholar
• Torrealba N, Rodríguez-Berriguete G, Vera R, et al. Homeostasis: apoptosis and cell cycle in normal and pathological prostate. Aging Male. 2018b;6:1–11.
   Web of Science ®Google Scholar
• Ivanović V, Todorović-Raković N, Demajo M, et al. Elevated plasma levels of transforming growth factor-beta 1 (TGF-beta 1) in patients with advanced breast cancer: association with disease progression. Eur J Cancer. 2003;39:454–461.
   PubMed Web of Science ®Google Scholar
• Wikström P, Damber J, Bergh A. Role of transforming growth factor-beta1 in prostate cancer. Microsc Res Tech. 2001;52:411–419.
   PubMed Web of Science ®Google Scholar
• Cohen-Solal KA, Boregowda RK, Lasfar A. RUNX2 and the PI3K/AKT axis reciprocal activation as a driving force for tumor progression. Mol Cancer. 2015;14:137.
   PubMed Web of Science ®Google Scholar
• Bakin AV, Tomlinson AK, Bhowmick NA, et al. Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem. 2000;275:36803–36810.
   PubMed Web of Science ®Google Scholar
• Li L, Ren CH, Tahir SA, et al. Caveolin-1 maintains activated AKT in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol Cell Biol. 2003;23:9389–9404.
   PubMed Web of Science ®Google Scholar
• Inoue Y, Imamura T. Regulation of TGF-beta family signaling by E3 ubiquitin ligases. Cancer Sci. 2008;99:2107–2112.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhou F, ten Dijke P. Signaling interplay between transforming growth factor-β receptor and PI3K/AKT pathways in cancer. Trends Biochem Sci. 2013;38:612–620.
   PubMed Web of Science ®Google Scholar
• Selvaraj N, Budka JA, Ferris MW, et al. Prostate cancer ETS rearrangements switch a cell migration gene expression program from RAS/ERK to PI3K/AKT regulation. Mol Cancer. 2014;13:61.
   PubMed Web of Science ®Google Scholar
• Guertin DA, Stevens DM, Saitoh M, et al. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell. 2009;15:148–159.
   PubMed Web of Science ®Google Scholar
• Evangelisti C, Ricci F, Tazzari P, et al. Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. Leukemia. 2011;25:781–791.
   PubMed Web of Science ®Google Scholar
• Presneau N, Shalaby A, Idowu B, et al. Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway. Br J Cancer. 2009;100:1406–1414.
   PubMed Web of Science ®Google Scholar
• Gravina GL, Marampon F, Petini F, et al. The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells. Endocr Relat Cancer. 2011;18:385–400.
   PubMed Web of Science ®Google Scholar
• Audet-Walsh É, Dufour CR, Yee T, et al. Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer. Genes Dev. 2017;31:1228–1242.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Berriguete G, Fraile B, Paniagua R, et al. Expression of NF-kB-related proteins and their modulation during TNF-α-provoked apoptosis in prostate cancer cells. Prostate. 2012;72:40–50.
   PubMed Web of Science ®Google Scholar
• Kaltschmidt B, Greiner JFW, Kadhim HM, et al. Subunit-Specific Role of NF-κB in Cancer. Biomedicines. 2018;6(2):44.
   PubMed Web of Science ®Google Scholar
• Bloom MJ, Saksena SD, Swain GP, et al. The effects of IKK-beta inhibition on early NF-kappa-B activation and transcription of downstream genes. Cell Signal. 2019;55:17–25.
   PubMed Web of Science ®Google Scholar
• Gamble C, McIntosh K, Scott R, et al. Inhibitory kappa B Kinases as targets for pharmacological regulation. Br J Pharmacol. 2012;165:802–819.
   PubMed Web of Science ®Google Scholar
• Affara NI, Coussens LM. IKKalpha at the crossroads of inflammation and metastasis. Cell. 2007;129:25–26.
   PubMed Web of Science ®Google Scholar
• Luo Y, Hurwitz J, Massagué J. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature. 1995;375:159–161.
   PubMed Web of Science ®Google Scholar
• Leopizzi M, Cocchiola R, Milanetti E, et al. IKKα inibition by a glucosamine derivative enhances Maspin expression in osteosarcoma cell line. Chem Biol Interact. 2017;262:19–28.
   PubMed Web of Science ®Google Scholar
• Nguyen DP, Li J, Yadav SS, et al. Recent insights into NF-KB signalling pathways and the link between inflammation and prostate cancer. BJU Int. 2014;114:168–176.
   PubMed Web of Science ®Google Scholar
• Jain G, Cronauer MV, Schrader M, et al. NF-κB signaling in prostate cancer: a promising therapeutic target? World J Urol. 2012;30:303–310.
   PubMed Web of Science ®Google Scholar
• Stancu C, Sima A. Statins: mechanism of action and effects. J Cell Mol Med. 2001;5:378–387.
   PubMed Web of Science ®Google Scholar
• Kang M, Lee KH, Lee HS, et al. Concurrent treatment with simvastatin and NF-κB inhibitor in human castration-resistant prostate cancer cells exerts synergistic anti-cancer effects via control of the NF-kB/LIN28/let-7 miRNA signaling pathway. PLoS One. 2017;12:e0184644.
   PubMed Web of Science ®Google Scholar
• Nunes JJ, Pandey SK, Yadav A, et al. Targeting NF-kappa B signaling by artesunate restores sensitivity of castrate-resistant prostate cancer cells to antiandrogens. Neoplasia. 2017;19:333–345.
   PubMed Web of Science ®Google Scholar